PCA
ALDX icon

Peddock Capital Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Peddock Capital Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-752
Closed -$4K – 107
2019
Q4 		$4K Buy
+752
New +$4.34K ﹤0.01% 233
2019
Q2 		– Sell
-752
Closed -$7K – 114
2019
Q1 		$7K Hold
752
– – ﹤0.01% 222
2018
Q4 		$6K Hold
752
– – ﹤0.01% 229
2018
Q3 		$10K Hold
752
– – ﹤0.01% 226
2018
Q2 		$6K Hold
752
– – ﹤0.01% 232
2018
Q1 		$6K Hold
752
– – ﹤0.01% 228
2017
Q4 		$5K Buy
+752
New +$4.95K ﹤0.01% 228

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Peddock Capital Advisors's ALDX Position: Q1 2020 in Review

Peddock Capital Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2020, closing a stake of 752 shares — an estimated $4K sold.

Peddock Capital Advisors first reported a position in ALDX in Q4 2017 and held it in 7 quarters. The position peaked at $10K in Q3 2018. 72 funds tracked by Wall St. Rank hold ALDX as of Q1 2020.

  • Peddock Capital Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Peddock Capital Advisors sold 752 Aldeyra Therapeutics shares in Q1 2020, an estimated $4K.
  • Peddock Capital Advisors first reported a position in Aldeyra Therapeutics in Q4 2017 and held it in 7 quarters.
  • Peddock Capital Advisors's Aldeyra Therapeutics position peaked at $10K in Q3 2018.
  • 72 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2020.

Based on Peddock Capital Advisors's 13F filing for Q1 2020, filed 13 May 2020.